We are live on
!
Find out more
BM
Bridger Management Portfolio holdings
AUM
$128M
1-Year Est. Return
9.54%
This Fund
S&P 500
This Quarter
Est. Return
+9.09%
1 Year Est. Return
+9.54%
3 Year Est. Return
+98.31%
5 Year Est. Return
+125.76%
10 Year Est. Return
+911.97%
AUM
$1.85B
AUM Growth
+$197M
(+12%)
Cap. Flow
+$123M
Cap. Flow
% of AUM
6.68%
Top 10 Holdings %
Top 10 Hldgs %
44.72%
Holding
42
New
5
Increased
15
Reduced
7
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HCA Healthcare
HCA
|
+$88.9M |
| 2 |
Amneal Pharmaceuticals
AMRX
|
+$37.6M |
| 3 |
Nektar Therapeutics
NKTR
|
+$35.8M |
| 4 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$25.1M |
| 5 |
Heron Therapeutics
HRTX
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$51.8M |
| 2 |
Labcorp
LH
|
+$48.1M |
| 3 |
Bank of America
BAC
|
+$28.3M |
| 4 |
DexCom
DXCM
|
+$19.2M |
| 5 |
Humana
HUM
|
+$12.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.5% |
| 2 | Consumer Discretionary | 11.23% |
| 3 | Technology | 8.75% |
| 4 | Communication Services | 8.56% |
| 5 | Consumer Staples | 5.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
GoDaddy
GDDY
$10.5B
| $106M | 5.73% |
1,496,992
| – | – |
|
2
Post Holdings
POST
$4.15B
| $97.5M | 5.28% |
1,731,238
| – | – |
|
|
MDCO
3
DELISTED
Medicines Co
MDCO
| $95.6M | 5.18% |
2,604,965
-52,521
| -2% | -$1.71M |
|
4
Atara Biotherapeutics
ATRA
$74.4M
| $90.4M | 4.9% |
98,370
-3,199
| -3% | -$3.44M |
|
|
5
HCA Healthcare
HCA
$86.9B
| $90.2M | 4.88% |
+878,761
| New | +$88.9M |
|
|
6
Heron Therapeutics
HRTX
$95.4M
| $77.6M | 4.2% |
1,997,697
+720,137
| +56% | +$22.9M |
|
7
Zimmer Biomet
ZBH
$18.1B
| $71.6M | 3.88% |
661,932
| – | – |
|
|
WCG
8
DELISTED
Wellcare Health Plans, Inc.
WCG
| $65.7M | 3.56% |
266,916
+16,577
| +7% | +$3.61M |
|
|
WMGI
9
DELISTED
Wright Medical Group Inc
WMGI
| $65.7M | 3.56% |
2,531,245
| – | – |
|
10
Caesars Entertainment
CZR
$6.06B
| $65.7M | 3.56% |
1,679,018
-176,232
| -9% | -$7.29M |
|
|
11
DexCom
DXCM
$32B
| $63.7M | 3.45% |
2,684,020
-906,460
| -25% | -$19.2M |
|
12
Alnylam Pharmaceuticals
ALNY
$27.1B
| $63.3M | 3.43% |
642,466
+92,834
| +17% | +$9.21M |
|
|
13
Humana
HUM
$44.1B
| $62.9M | 3.41% |
211,407
-42,839
| -17% | -$12.5M |
|
|
14
Labcorp
LH
$25.5B
| $61.2M | 3.32% |
396,795
-318,625
| -45% | -$48.1M |
|
|
15
Nektar Therapeutics
NKTR
$2.38B
| $55.4M | 3% |
75,628
+31,062
| +70% | +$35.8M |
|
16
Charter Communications
CHTR
$17.4B
| $55.2M | 2.99% |
188,164
+47,704
| +34% | +$13.7M |
|
17
Morgan Stanley
MS
$332B
| $54.2M | 2.94% |
1,143,109
+66,300
| +6% | +$3.46M |
|
18
MGM Resorts International
MGM
$11.4B
| $49.8M | 2.7% |
1,714,192
+190,860
| +13% | +$6.16M |
|
19
Armstrong World Industries
AWI
$7.32B
| $48.6M | 2.63% |
769,622
| – | – |
|
|
SGI
20
Somnigroup International
SGI
$14B
| $44.4M | 2.4% |
3,695,516
+678,484
| +22% | +$8M |
|
21
Meta Platforms (Facebook)
META
$1.4T
| $41.1M | 2.23% |
211,473
+36,742
| +21% | +$6.64M |
|
|
DRNA
22
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $39.5M | 2.14% |
3,225,527
+1,998,707
| +163% | +$25.1M |
|
23
Viasat
VSAT
$10.6B
| $37.5M | 2.03% |
570,979
| – | – |
|
24
Teva Pharmaceuticals
TEVA
$40.9B
| $36.5M | 1.98% |
1,500,000
+750,000
| +100% | +$15.3M |
|
|
25
Amneal Pharmaceuticals
AMRX
$5.84B
| $35.2M | 1.91% |
+2,143,621
| New | +$37.6M |
|
Similar funds
SHFC
IUC
PC
SIM
PIA
S
CF
BC
Bridger Management's Q2 2018 Portfolio in Review
As of Q2 2018, Bridger Management held 42 positions worth $1.85B, up 12% from $1.65B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Bridger Management deployed $123M of net new capital in Q2 2018, opening 5 new positions and adding to 15 existing holdings. Its largest new stake was HCA Healthcare: 878,761 shares worth $90.2M.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 48% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Labcorp, an estimated $48.1M trimmed.
- Bridger Management's largest Q2 2018 buy was HCA Healthcare: 878,761 shares worth $90.2M.
- Bridger Management added most to Nektar Therapeutics in Q2 2018, an estimated $35.8M increase.
- Bridger Management's biggest Q2 2018 reduction was Labcorp, cutting an estimated $48.1M.
- Bridger Management fully exited Incyte in Q2 2018, selling an estimated $51.8M.
- Bridger Management's ten largest holdings make up 45% of its $1.85B portfolio in Q2 2018.
- Bridger Management opened 5 new positions and closed 5 in Q2 2018.
- Bridger Management's portfolio value rose 12% quarter-over-quarter to $1.85B.
Based on Bridger Management's 13F filing for Q2 2018, filed 14 Aug 2018.